Jul. 9 at 11:18 PM
$KOD Recent Updates on Tarcocimab Tedromer:
1. **GLOW2 Trial Enrollment Completion**: Kodiak Sciences has completed enrollment in the GLOW2 phase 3 clinical trial for Tarcocimab tedromer, which is being evaluated for its efficacy in treating diabetic retinopathy (DR). This trial involves over 250 treatment-naïve patients and aims to assess the drug's effectiveness compared to sham injections. The primary endpoint is a ≥2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at week 48. Topline data from this trial is expected in Q1 2026.
2. **Previous Successes**: Tarcocimab has shown promising results in earlier studies, including the GLOW1 trial, where it significantly improved DR severity scores and reduced sight-threatening complications. The drug is designed to provide a biannual dosing regimen, which could transform the treatment landscape for diabetic retinopathy.
[More in comments]
